18FDG PET/MR Reliability in Imaging Patients with Cancer

Status: closed to accrual and intervention

This clinical trial studies fludeoxyglucose F-18 (18FDG) positron emission tomography (PET)/magnetic resonance (MR) in imaging patients with cancer. 18F-FDG is a radioactive substance that is taken up more by cancer cells then normal cells making them lighting up. PET uses a scanner to make detailed, computerized pictures of areas inside the body where the radioactive substance is lighting up. MR is a procedure in which radio waves and a powerful magnet linked to a computer are used to create detailed pictures of areas inside the body. These pictures can show the difference between normal and diseased tissue. It is very important with medical imaging procedures to know how well a scan can be reproduced. Therefore, doctors want to know whether PET/MR scans taken on multiple occasions in patients with cancer show the same results and compared with the results of 18FDG PET/computed tomography (CT).

Inclusion Criteria

Patients with histologically confirmed malignancy (local or metastatic, newly diagnosed or recurrent disease)
Patient must have at least one area of disease measuring >= 1.0 cm
Ability to provide informed consent

Exclusion Criteria

Uncontrolled intercurrent illness including, but not limited to active infections
Patients with insulin-dependent diabetes
Patients with metal devices in the body including, but not limited to metallic joint prostheses, artificial heart valves, pacemakers, and cochlear implants
Patients who are pregnant or nursing
Inability to tolerate 60 minutes of PET imaging
Inability to comply with study procedures

PRIMARY OBJECTIVE:

I. To evaluate the variability of repeated quantitative measures of FDG (fludeoxyglucose F-18) uptake on PET/MR in patients with malignancy.

II. To study the repeatability of diffusion-weighted imaging on PET/MR.

SECONDARY OBJECTIVES:

I. To evaluate the reproducibility of the ratio of maximum standardized uptake value (SUVmax) and minimum apparent diffusion coefficient (ADCmin) (SUVmax/ADCmin).

OUTLINE:

Patients receive 18FDG intravenously (IV). Beginning 60 minutes later, patients undergo PET/CT scan over 40 minutes. Patients then receive glucagon IV and undergo PET/MRI. Patients undergo a repeat imaging session including a PET/CT scan followed immediately by a PET/MR within 3 months.

Have a question?
We're here to help

Chat with us: LiveHelp
Call us: 1-800-4-CANCER
(1-800-422-6237)

Which trials are right for you?

Use the checklist in our guide to gather the information you’ll need.

18FDG PET/MR Reliability in Imaging Patients with Cancer

Description

Eligibility Criteria

Locations & Contacts

Trial Objectives and Outline

Trial Phase & Type

Lead Organization

Trial IDs

Have a question?We're here to help

Which trials are right for you?

Have a question?
We're here to help